US2019261623A1PendingUtilityA1

Cell composition and methods of making the same

47
Assignee: CELULARITY INCPriority: Aug 20, 2008Filed: Sep 21, 2018Published: Aug 29, 2019
Est. expiryAug 20, 2028(~2.1 yrs left)· nominal 20-yr term from priority
Inventors:Andy ZeitlinGregory RussottiShuyang HeAjai PalHong ChenThomas BrievaBryan Patrick Murphy
A61P 7/00A61P 43/00A61P 19/00A61P 19/04A01N 1/0221A01N 1/125C12N 5/0605A61K 35/50
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby.

Claims

exact text as granted — not AI-modified
1 - 28 . (canceled) 
     
     
         29 . A composition comprising a plurality of isolated human adherent placental cells in a solution comprising 10% dextran 40, wherein said composition comprises between about 1.0±0.3×106 cells per milliliter to about 5.0±1.5×106 cells per milliliter, and wherein said composition comprises no macro cell clumps. 
     
     
         30 . The composition of  claim 29 , wherein said placental stem cells are thawed cryopreserved cells. 
     
     
         31 . The composition of  claim 29 , wherein said composition is contained within a bag. 
     
     
         32 . The composition of  claim 29 , wherein said composition comprises no macro cell clumps. 
     
     
         33 . The composition of  claim 29 , wherein said composition comprises fewer than about 200 micro cell clumps per 106 cells. 
     
     
         34 . The composition of  claim 29 , wherein said composition comprises fewer than about 150 micro cell clumps per 106 cells. 
     
     
         35 . The composition of  claim 29 , wherein said composition comprises fewer than about 100 micro cell clumps per 106 cells. 
     
     
         36 . The composition of  claim 29 , wherein said isolated human adherent placental cells are CD10+, CD34− and CD105+. 
     
     
         37 . The composition of  claim 36 , wherein said CD10+, CD34− and CD105+ cells are CD200+. 
     
     
         38 . The composition of  claim 37 , wherein said CD10+, CD34−, and CD105+ and CD200+ cells are either CD45− or CD90+. 
     
     
         39 . The composition of  claim 37 , wherein said CD10+, CD34−, and CD105+ and CD200+ cells are CD45− or CD90+. 
     
     
         40 . The composition of  claim 29 , wherein said composition is a pharmaceutical composition. 
     
     
         41 - 42 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.